ArticleJournal of inflammation research2025
Repeated Mesenchymal Stem Cell Delivery Attenuates UHMWPE Wear Particle-Induced Osteolysis by Paracrine-Mediated Macrophage Reprogramming.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Periprosthetic osteolysis (PPO) induced by ultra-high molecular weight polyethylene (UHMWPE) particles remains a major clinically challenging problem in joint arthroplasty. This study investigated whether local delivery of bone marrow mesenchymal stem cells (BMSCs) could alleviate UHMWPE-induced bone destruction by modulating macrophage polarization. Methods: In vivo, a murine calvarial osteolysis model was established and divided into four groups: Sham, UHMWPE-induced osteolysis (PIO), single BMSC injection (BMSCs-1), and repeated BMSC injection (BMSCs-2) groups. In vitro, RAW264.7 macrophages were treated under five conditions: RAW264.7 alone, BMSCs alone, RAW264.7+BMSCs, RAW264.7 + UHMWPE, and RAW264.7 + UHMWPE + BMSCs in a transwell co-culture system. Bone parameters (BMD, BV/TV, Tb.Th, and Tb.N) were evaluated by micro-CT; Macrophage polarization and cytokine expression were assessed by histology, immunohistochemistry (IHC), flow cytometry, ELISA, and immunofluorescence. Results: In vivo, BMSC administration markedly improved bone parameters and mitigated UHMWPE-induced osteolysis, with repeated dosing showing more efficacy than a single dose compared to the PIO group. BMSC treatment suppressed M1 (CD80⁺) macrophage infiltration, enhanced M2 (CD206⁺) polarization, and rebalanced cytokine expression by reducing TNF-α and increasing IL-10 levels. In vitro, the BMSC transwell co-culture system consistently promoted M2 polarization and anti-inflammatory cytokine secretion in UHMWPE-stimulated macrophages, confirming the paracrine-mediated immunomodulatory effect. Conclusion: Local BMSC therapy, particularly with repeated dosing, effectively attenuated UHMWPE-induced osteolysis by reprogramming macrophage polarization through paracrine signaling. These findings highlight a potential translational strategy for stem cell-based treatment of periprosthetic osteolysis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.